Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) Lipidomics Study

Epigenome-Wide Association Study of Fasting Blood Lipids in the Genetics of Lipid-Lowering Drugs and Diet Network Study

M. Irvin, Degui Zhi, R. Joehanes, et al.. (2014). Circulation. Cited 195 times. https://doi.org/10.1161/CIRCULATIONAHA.114.009158

Association of DNA Methylation at CPT1A Locus with Metabolic Syndrome in the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) Study

M. Das, Jin Sha, Bertha A. Hidalgo, et al.. (2016). PLoS ONE. Cited 67 times. https://doi.org/10.1371/journal.pone.0145789

A genome-wide association study of inflammatory biomarker changes in response to fenofibrate treatment in the Genetics of Lipid Lowering Drug and Diet Network

S. Aslibekyan, E. Kabagambe, M. Irvin, et al.. (2012). Pharmacogenetics and Genomics. Cited 61 times. https://doi.org/10.1097/FPC.0b013e32834fdd41

Genomics of Post-Prandial Lipidomic Phenotypes in the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) Study

(2014). PLoS ONE. Cited 25 times. https://doi.org/10.1371/journal.pone.0099509

Rare PPARA variants and extreme response to fenofibrate in the Genetics of Lipid-Lowering Drugs and Diet Network Study

M. Irvin, Qunyuan Zhang, E. Kabagambe, et al.. (2012). Pharmacogenetics and Genomics. Cited 11 times. https://doi.org/10.1097/FPC.0b013e328351a486